Of course everything our expert says is reasonable
Cellestis has achieved strong revenue and earnings growth in the past few years and is expected to continue to do so in the near term
and everything shareholders say is unreasonable
in our opinion, the revenue growth assumptions adopted in the CSAG Model are optimistic.
When it comes down to comparable revenue growth they do admit that
There are no other listed companies whose only product is a diagnostic test for latent tuberculosis
so they compared Cellestis revenue growth with large global healthcare companies, which is somehow reasonable.
